Ignite Creation Date:
2025-12-24 @ 4:15 PM
Ignite Modification Date:
2025-12-25 @ 2:13 PM
Study NCT ID:
NCT00305266
Status:
COMPLETED
Last Update Posted:
2007-12-03
First Post:
2006-03-20
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Study of CIDP Patients During IVIG Treatment
Sponsor:
University of Aarhus
Organization:
Study Overview
Official Title:
"Clinical Study of Intravenous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy"
Status:
COMPLETED
Status Verified Date:
2007-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this study is to quantify the effect of IVIG treatment in a group of patients with chronic inflammatory demyelinating polyradiculoneuropathy(CIDP), who requires continues treatment of IVIG at regular intervals of 3-10 weeks:
1. During continues treatment of IVIG at regular intervals of 3-10 weeks.
2. During pause in treatment.
Hypothesis:
1. The disease activity in the patients are cyclical correlating to the treatment intervals.
2. Pause in treatment will increase disease activity, which can be quantified with symptom scores, disability scales, and clinical test.
Primary effect parameter is muscle strength quantified by isokinetic dynamometry.
Added to the protocol there is an immunological study of inflammatory markers in blood samples of patients under treatment pause.
1. During continues treatment of IVIG at regular intervals of 3-10 weeks.
2. During pause in treatment.
Hypothesis:
1. The disease activity in the patients are cyclical correlating to the treatment intervals.
2. Pause in treatment will increase disease activity, which can be quantified with symptom scores, disability scales, and clinical test.
Primary effect parameter is muscle strength quantified by isokinetic dynamometry.
Added to the protocol there is an immunological study of inflammatory markers in blood samples of patients under treatment pause.
Detailed Description:
Background: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare autoimmune disease of the peripheral nervous system characterized by demyelination of the nerves, which causes muscle weakness and sensory loss. Treatment is immune modulating, and intravenous immunoglobulin (IVIG) is first line therapy.Several trials have demonstrated effect on motor function by the initial treatment, but the effect of consecutive IVIG treatment is only sporadic described in the literature.
It is a clinical study including present CIDP patients in treatment at the University Hospital of Aarhus. The patients will be evaluated several times before and after IVIG treatment, to describe the effect profile.
The primary effect parameter is muscle strength quantified by isokinetic dynamometry at ankle knee, hip, wrist, elbow and shoulder. That is a sensitive method of measuring the strength of the larger muscle groups, correlating with symptoms and signs of neuropathy.
Severity of neuropathy among the patients will also be described applying nerve conduction studies, quantitative sensory testing of threshold for detecting vibration and cold at upper and lower limbs, the Neuropathy Disability Scale, the Neuropathy Symptom Score,the overall disability sum score, 9 hole peg test, walking test, and the Short-form 36 health questionnaire.
Added to the protocol there is an immunological study of inflammatory markers in blood samples of patients under treatment pause.
Objective:
With this study we will describe some important aspects in the immune response causing the inflammatory lesions in CIDP and MMN, including:
1. Recruitment of immune cells to the affected tissue by chemoattraction. (Chemokine receptors on mononuclear cells)
2. Crossing the blood-nerve barrier: interactions and adhesion between the lymphocyte and endothelial cell, transendothelial diapedesis and enzymatic degeneration of the basal lamina.(Adhesion molecules on mononuclear cells and soluble in plasma, metalloproteinases)
3. Synthesis of mRNA and secretion of regulatory cytokines.
It is a clinical study including present CIDP patients in treatment at the University Hospital of Aarhus. The patients will be evaluated several times before and after IVIG treatment, to describe the effect profile.
The primary effect parameter is muscle strength quantified by isokinetic dynamometry at ankle knee, hip, wrist, elbow and shoulder. That is a sensitive method of measuring the strength of the larger muscle groups, correlating with symptoms and signs of neuropathy.
Severity of neuropathy among the patients will also be described applying nerve conduction studies, quantitative sensory testing of threshold for detecting vibration and cold at upper and lower limbs, the Neuropathy Disability Scale, the Neuropathy Symptom Score,the overall disability sum score, 9 hole peg test, walking test, and the Short-form 36 health questionnaire.
Added to the protocol there is an immunological study of inflammatory markers in blood samples of patients under treatment pause.
Objective:
With this study we will describe some important aspects in the immune response causing the inflammatory lesions in CIDP and MMN, including:
1. Recruitment of immune cells to the affected tissue by chemoattraction. (Chemokine receptors on mononuclear cells)
2. Crossing the blood-nerve barrier: interactions and adhesion between the lymphocyte and endothelial cell, transendothelial diapedesis and enzymatic degeneration of the basal lamina.(Adhesion molecules on mononuclear cells and soluble in plasma, metalloproteinases)
3. Synthesis of mRNA and secretion of regulatory cytokines.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| EudraCT nr.: 2004-004357-26 | None | None | View |